the product in the database has an inactive status
indications:
Peptic ulcer of the stomach and duodenum (treatment and prophylaxis), gastro-oesophageal reflux and other conditions with excessive secretion of gastric juice (eg Zollinger-Ellison syndrome).
Composition:
1 tabl powl. contains 20 mg or 40 mg famotidine.
Action:
A competitive inhibitor of histamine H receptors2. Famotidine inhibits the secretion of hydrochloric acid in the stomach. It reduces both the acidity and volume of gastric juice, while the reduction of pepsin secretion is proportional to the amount of gastric juice secretion. Famotidine inhibits the basic and nocturnal secretion of hydrochloric acid, as well as stimulated by pentagastrin, betazol, Caffeine, insulin and a physiological reflex of the vagus nerve. The time of inhibition of secretion after doses of 20 and 40 mg is 10-12 h. The bioavailability is 40-45%. The maximum concentration in the blood occurs after 1-3 hours. The plasma proteins bind in 15-20%. It is metabolized in the liver. It is excreted in the urine (65-70%) and metabolic pathways (30-35%). 25-60% of the oral dose is excreted in the urine in unchanged form. T0,5 in the blood is 2.3-3.5 hours. In patients with severe renal impairment (creatinine clearance below 10 ml / min), the half-life may exceed 20 hours.
Contraindications:
Hypersensitivity to the components of the preparation and other medicines from the group of H receptor antagonists2. Children.
Precautions:
Special care should be taken in patients with renal insufficiency. Due to the lactose content, the preparation should not be used in patients with rare hereditary galactose intolerance, lactose intolerance (Lapp type) or malabsorption of glucose-galactose.
Pregnancy and lactation:
In pregnancy, the drug can only be used if clearly necessary. Famotidine passes into breast milk - during breastfeeding, a choice should be made between discontinuation of feeding and further administration.
Side effects:
Uncommon: fatigue, transient psychiatric disorders (depression, confusion, confusion, anxiety, agitation and hallucinations), nausea, vomiting, discomfort or abdominal pain, anorexia, dry mouth, increased liver enzymes, cholestatic jaundice, rash , pruritus, urticaria, anaphylaxis, angioneurotic edema, pain in the joints and muscles, muscle cramps. Rarely: pain and dizziness, constipation, diarrhea. Very rare: toxic necrotic epidermal separation, atrioventricular block and gynecomastia, which disappears after discontinuation of the drug. In addition, rare cases of leukopenia, pancytopenia, thrombocytopenia and agranulocytosis and exacerbation of existing liver disease have been observed, however, no causal relationship between famotidine treatment and the occurrence of these side effects has been confirmed.
Dosage:
Orally. Duodenal ulcer: treatment - 40 mg once daily at bedtime or 20 mg twice daily (morning and evening) for 4-8 weeks; prevention - 20 mg once daily at bedtime. Peptic ulcer: 40 mg once daily at bedtime for 4-8 weeks. Gastro-oesophageal reflux: 20 mg twice daily (morning and evening) for 6-12 weeks; if gastro-oesophageal reflux is associated with erosive or esophageal inflammation, a 40-mg dose is recommended 2 times a day for 12 weeks. Zollinger-Ellison syndrome: the starting dose is usually 20 mg every 6 hours for patients who have not previously been used another treatment to suppress the secretion of gastric juice, then the dose should be adjusted individually depending on the patient's condition; in patients previously treated with another H2-receptor antagonist, the starting dose may be increased. In renal insufficiency with a creatinine clearance below 10 ml / min, the daily dose should be reduced to 20 mg.